FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791905615> ?p ?o ?g. }

• W2791905615 endingPage "1991" @default.
• W2791905615 startingPage "1982" @default.
• W2791905615 abstract "BACKGROUND The best treatment for patients with advanced non–small cell lung cancer (NSCLC) and a poor performance status is not well defined. In this phase 2 trial, patients were randomized to receive treatment with either single-agent pemetrexed or 1 of 2 combination regimens. METHODS Patients with newly diagnosed, histologically confirmed nonsquamous NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 were stratified by age and serum albumin level and were randomized (1:1:1) to 1 of 3 regimens: pemetrexed (arm 1), pemetrexed and bevacizumab (arm 2), or pemetrexed, carboplatin, and bevacizumab (arm 3). The response to treatment was assessed every 2 cycles; responding and stable patients continued treatment until progression or unacceptable toxicity. RESULTS One hundred seventy-two patients were randomized, 162 patients began the study treatment, and 146 patients completed 2 cycles and were evaluated for their response. The median progression-free survival (PFS) was 2.8 months in arm 1, 4.0 months in arm 2, and 4.8 months in arm 3. The overall response rates were 15% in arm 1, 31% in arm 2, and 44% in arm 3. The overall survival was similar in the 3 treatment arms. All 3 regimens were relatively well tolerated. Patients receiving bevacizumab had an increased incidence of hypertension, proteinuria, and bleeding episodes, but most events were mild or moderate. CONCLUSIONS All 3 regimens were feasible for patients with advanced NSCLC and an ECOG performance status of 2. The addition of bevacizumab to pemetrexed increased the overall response rate. The efficacy of pemetrexed/carboplatin/bevacizumab (median PFS, 4.8 months) approached the prespecified study PFS goal of 5 months. Larger studies will be necessary to define the role of bevacizumab in addition to standard pemetrexed and carboplatin in this population. Cancer 2018;124:1982-91. © 2018 American Cancer Society." @default.
• W2791905615 created "2018-03-29" @default.
• W2791905615 creator A5016133976 @default.
• W2791905615 creator A5018054038 @default.
• W2791905615 creator A5035910746 @default.
• W2791905615 creator A5065917441 @default.
• W2791905615 creator A5072308451 @default.
• W2791905615 creator A5073724595 @default.
• W2791905615 creator A5079398298 @default.
• W2791905615 creator A5088493957 @default.
• W2791905615 date "2018-02-16" @default.
• W2791905615 modified "2023-10-18" @default.
• W2791905615 title "Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2" @default.
• W2791905615 cites W1982488143 @default.
• W2791905615 cites W1990626198 @default.
• W2791905615 cites W2019607817 @default.
• W2791905615 cites W2043696829 @default.
• W2791905615 cites W2052335855 @default.
• W2791905615 cites W2077520669 @default.
• W2791905615 cites W2079123814 @default.
• W2791905615 cites W2097268198 @default.
• W2791905615 cites W2099725888 @default.
• W2791905615 cites W2104830962 @default.
• W2791905615 cites W2120742888 @default.
• W2791905615 cites W2130652363 @default.
• W2791905615 cites W2135140316 @default.
• W2791905615 cites W2137009016 @default.
• W2791905615 cites W2144660856 @default.
• W2791905615 cites W2145835533 @default.
• W2791905615 cites W2156353875 @default.
• W2791905615 cites W2160131381 @default.
• W2791905615 cites W2162328883 @default.
• W2791905615 cites W4239714259 @default.
• W2791905615 cites W4293241248 @default.
• W2791905615 doi "https://doi.org/10.1002/cncr.30986" @default.
• W2791905615 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29451696" @default.
• W2791905615 hasPublicationYear "2018" @default.
• W2791905615 type Work @default.
• W2791905615 sameAs 2791905615 @default.
• W2791905615 citedByCount "12" @default.
• W2791905615 countsByYear W27919056152018 @default.
• W2791905615 countsByYear W27919056152019 @default.
• W2791905615 countsByYear W27919056152020 @default.
• W2791905615 countsByYear W27919056152021 @default.
• W2791905615 countsByYear W27919056152022 @default.
• W2791905615 countsByYear W27919056152023 @default.
• W2791905615 crossrefType "journal-article" @default.
• W2791905615 hasAuthorship W2791905615A5016133976 @default.
• W2791905615 hasAuthorship W2791905615A5018054038 @default.
• W2791905615 hasAuthorship W2791905615A5035910746 @default.
• W2791905615 hasAuthorship W2791905615A5065917441 @default.
• W2791905615 hasAuthorship W2791905615A5072308451 @default.
• W2791905615 hasAuthorship W2791905615A5073724595 @default.
• W2791905615 hasAuthorship W2791905615A5079398298 @default.
• W2791905615 hasAuthorship W2791905615A5088493957 @default.
• W2791905615 hasBestOaLocation W27919056151 @default.
• W2791905615 hasConcept C126322002 @default.
• W2791905615 hasConcept C141071460 @default.
• W2791905615 hasConcept C143998085 @default.
• W2791905615 hasConcept C168563851 @default.
• W2791905615 hasConcept C2776256026 @default.
• W2791905615 hasConcept C2776694085 @default.
• W2791905615 hasConcept C2776907518 @default.
• W2791905615 hasConcept C2777240266 @default.
• W2791905615 hasConcept C2777802072 @default.
• W2791905615 hasConcept C2778239845 @default.
• W2791905615 hasConcept C2781451048 @default.
• W2791905615 hasConcept C71924100 @default.
• W2791905615 hasConceptScore W2791905615C126322002 @default.
• W2791905615 hasConceptScore W2791905615C141071460 @default.
• W2791905615 hasConceptScore W2791905615C143998085 @default.
• W2791905615 hasConceptScore W2791905615C168563851 @default.
• W2791905615 hasConceptScore W2791905615C2776256026 @default.
• W2791905615 hasConceptScore W2791905615C2776694085 @default.
• W2791905615 hasConceptScore W2791905615C2776907518 @default.
• W2791905615 hasConceptScore W2791905615C2777240266 @default.
• W2791905615 hasConceptScore W2791905615C2777802072 @default.
• W2791905615 hasConceptScore W2791905615C2778239845 @default.
• W2791905615 hasConceptScore W2791905615C2781451048 @default.
• W2791905615 hasConceptScore W2791905615C71924100 @default.
• W2791905615 hasFunder F4320332193 @default.
• W2791905615 hasIssue "9" @default.
• W2791905615 hasLocation W27919056151 @default.
• W2791905615 hasLocation W27919056152 @default.
• W2791905615 hasOpenAccess W2791905615 @default.
• W2791905615 hasPrimaryLocation W27919056151 @default.
• W2791905615 hasRelatedWork W1970261786 @default.
• W2791905615 hasRelatedWork W2013653877 @default.
• W2791905615 hasRelatedWork W2274549781 @default.
• W2791905615 hasRelatedWork W2536347864 @default.
• W2791905615 hasRelatedWork W2754651043 @default.
• W2791905615 hasRelatedWork W2774698410 @default.
• W2791905615 hasRelatedWork W2791905615 @default.
• W2791905615 hasRelatedWork W2805443924 @default.
• W2791905615 hasRelatedWork W2947864948 @default.
• W2791905615 hasRelatedWork W3029430426 @default.
• W2791905615 hasVolume "124" @default.
• W2791905615 isParatext "false" @default.

• next